ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018
Update on
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Pooled it
- Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries.World journal of urology · 2021Pooled it
- The Diagnostic Role ofFrontiers in oncology · 2021Pooled it
- [European journal of nuclear medicine and molecular imaging · 2020Guideline
- Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Trial
- Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.The Journal of urology · 2019Trial
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
- Preclinical Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Physiological biodistribution ofFrontiers in nuclear medicine · 2026Article
- High-risk biochemical recurrence in prostate cancer: identification and early intervention strategies.Frontiers in urology · 2026Review
- Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Observational
- Performance and application of the total-body PET/CT scanner: a literature review.EJNMMI research · 2024Review
- Decomposition of medical imaging spending growth between 2010 and 2021 in the US employer-insured population.Health affairs scholar · 2024Article
- Assessing the effectiveness of MRI,Polish journal of radiology · 2024Article
- Article
- A prospective comparative study of [European journal of nuclear medicine and molecular imaging · 2023Article
- Review
- Article
- Mask R-CNN assisted 2.5D object detection pipeline ofScientific reports · 2023Article
- Clinical practice in prostate PET imaging.Therapeutic advances in medical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PET is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Anti-1-amino-3-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.